Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Earnings call transcript: Trevi Therapeutics Q4 2025 earnings beat expectations
Trevi Therapeutics reported Q4 2025 earnings that surpassed analyst expectations with an EPS of -0.06 USD against a forecast of -0.10 USD. Despite this positive surprise and a strong cash position extending into 2028, the stock saw a slight decline in aftermarket trading. The company plans to initiate two pivotal Phase 3 trials for IPF-related chronic cough in 2026 and expand its clinical reach into non-IPF ILD, with analysts maintaining a bullish outlook.